A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : CTCAE

Search Conditions:
Search Keyword : CTCAE
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: CTCAE
Appearance Frequency: 571 time(s)
Long forms: 19

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
Common Terminology Criteria for Adverse Events
(541 times)
Neoplasms
(323 times)
OS (59 times)
AEs (39 times)
IMRT (35 times)
2004 [Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines].
Criteria for Adverse Effects
(5 times)
Neoplasms
(2 times)
HCC (2 times)
AHOs (1 time)
B-TACE (1 time)
2014 [The preliminary study of recombinant adenovirus p53 combined with transarterial embolization with particles for advanced hepatocellular carcinoma].
Common Terminology Criteria for AEs
(4 times)
Neoplasms
(2 times)
AE (2 times)
AEs (2 times)
HFS (2 times)
2017 Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer.
Common Terminology Criteria
(3 times)
Neoplasms
(3 times)
AE (1 time)
CIPN (1 time)
CRT (1 time)
2012 A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
Clinical Trials Classification of Adverse Events
(2 times)
Rheumatology
(2 times)
IRR (2 times)
RA (1 time)
RTX (1 time)
2013 Rapid infusion with rituximab: short term safety in systemic autoimmune diseases.
Common Toxicity Criteria
(2 times)
Biophysics
(1 time)
CFA (1 time)
CIPN (1 time)
EFA (1 time)
2017 Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study.
Common Toxicity Criteria for AE
(2 times)
Neoplasms
(2 times)
AE (1 time)
AsPn (1 time)
IMRT (1 time)
2011 A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer.
Clinically Adverse Events nomenclature
(1 time)
Abdomen
(1 time)
HCC (1 time)
2018 Feasibility and outcomes of percutaneous thermal ablation of hepatocellular carcinoma in a transplanted allograft.
collect and determine agreement between physician assessed toxicity
(1 time)
Neoplasms
(1 time)
AC (1 time)
CRT (1 time)
PRO (1 time)
2018 Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization.
10  common criteria for adverse events
(1 time)
HCC (1 time)
IHC (1 time)
LC (1 time)
2016 Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience.
11  Common Toxicity Criteria for adverse event reporting
(1 time)
Neoplasms
(1 time)
18F-F Miso (1 time)
18F-FDG (1 time)
18F-FLT (1 time)
2020 MRI- and PET-Guided Interstitial Brachytherapy for Postsurgical Vaginal Recurrences of Cervical Cancer: Results of Phase II Study.
12  common treatment-related AEs ≥Common Terminology Criteria for AE
(1 time)
Urology
(1 time)
AEs (1 time)
CTCs (1 time)
mCRPC (1 time)
2020 PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
13  convincingly for obligatory and standardised behaviour on adverse events
(1 time)
Microbiology
(1 time)
--- 2014 Probiotic and synbiotic safety in infants under two years of age.
14  Criteria for Acute Events
(1 time)
Urology
(1 time)
BT (1 time)
EBRT (1 time)
GI (1 time)
2013 Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
15  criteria for adverse events from the National Cancer Institute
(1 time)
Neoplasms
(1 time)
ADT (1 time)
bRFS (1 time)
GI (1 time)
2014 Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer.
16  Criteria for Adverse Events scale
(1 time)
Neoplasms
(1 time)
CT (1 time)
HDR-IRT (1 time)
NMSC (1 time)
2019 The role of personalized Interventional Radiotherapy (brachytherapy) in the management of older patients with non-melanoma skin cancer.
17  Criteria for Common Adverse Events
(1 time)
Urology
(1 time)
CI (1 time)
LuPSMA (1 time)
PCWG3 (1 time)
2020 Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.
18  criteria from the National Cancer Institute
(1 time)
Neoplasms
(1 time)
--- 2011 Informatics in clinical research in oncology: current state, challenges, and a future perspective.
19  cumulative hematologic III
(1 time)
Neoplasms
(1 time)
FFR (1 time)
ITT (1 time)
nCRT (1 time)
2017 Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus.